Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.27
+8.0%
$7.85
$5.01
$18.71
$51.15M0.18117,317 shs41,364 shs
Curis, Inc. stock logo
CRIS
Curis
$1.85
+6.3%
$2.19
$1.02
$8.29
$18.20M3.680,965 shs168,278 shs
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.63
+1.2%
$1.20
$1.78
$40.66
$49.15M1.4620,672 shs253,336 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.45
-0.8%
$11.26
$5.78
$22.00
$1.35B2.39276,578 shs235,419 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.05
+8.2%
$0.91
$0.52
$1.98
$283.27M4.184.57 million shs5.12 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+8.04%+18.85%+0.43%+57.39%+16.46%
Curis, Inc. stock logo
CRIS
Curis
+6.32%-13.95%-21.94%+51.64%-72.24%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+1.24%-1.21%+39.32%+45.54%+126.39%
Mesoblast Limited stock logo
MESO
Mesoblast
-0.76%-13.78%-11.37%-5.69%+35.19%
Ocugen, Inc. stock logo
OCGN
Ocugen
+8.25%+13.62%-0.94%+51.41%-39.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.0952 of 5 stars
3.33.00.04.70.62.50.6
Curis, Inc. stock logo
CRIS
Curis
2.8718 of 5 stars
3.55.00.00.02.30.00.6
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
1.9787 of 5 stars
3.51.00.00.02.50.80.6
Ocugen, Inc. stock logo
OCGN
Ocugen
0.9682 of 5 stars
3.51.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.7591.48% Upside
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00818.92% Upside
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0072.25% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00471.43% Upside

Current Analyst Ratings Breakdown

Latest OCGN, ATRA, MESO, CRTX, and CRIS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$128.94M0.43N/AN/A($16.89) per share-0.55
Curis, Inc. stock logo
CRIS
Curis
$10.91M1.77N/AN/A($0.71) per share-2.61
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M226.32N/AN/A$4.21 per share2.48
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M75.71N/AN/A$0.10 per share10.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)
Curis, Inc. stock logo
CRIS
Curis
-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/14/2025 (Estimated)

Latest OCGN, ATRA, MESO, CRTX, and CRIS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/9/2025Q1 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05N/A$1.48 million
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.57
0.57
Curis, Inc. stock logo
CRIS
Curis
N/A
1.23
1.23
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63
Ocugen, Inc. stock logo
OCGN
Ocugen
1.74
2.60
2.60

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Curis, Inc. stock logo
CRIS
Curis
29.97%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.00%
Curis, Inc. stock logo
CRIS
Curis
5.70%
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.72 millionOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million9.87 millionNo Data
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.03 million279.50 millionOptionable

Recent News About These Companies

Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen To Present at BIO International Convention 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.27 +0.69 (+8.04%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$9.26 -0.01 (-0.11%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Curis stock logo

Curis NASDAQ:CRIS

$1.85 +0.11 (+6.32%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.94 +0.10 (+5.14%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.63 +0.02 (+1.24%)
As of 07/7/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.45 -0.08 (-0.76%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$10.34 -0.11 (-1.10%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.05 +0.08 (+8.25%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.05 0.00 (0.00%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.